Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Interventional × Alemtuzumab × Clear all

Phase

Status

Completed 77 Terminated 30 Unknown 12 Withdrawn 3 Active not recruiting 3 Suspended 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1

Interventions

Cisplatin 105 Carboplatin 103 Drug Therapy 91 Oxaliplatin 86 Capecitabine 79 Bevacizumab 78 Paclitaxel 76 pembrolizumab 74 Cyclophosphamide 73 Gemcitabine 72 Radiotherapy 71 tislelizumab 68 Specimen Handling 56 toripalimab 54 Fluorouracil 54 Injections 48 sintilimab 47 Docetaxel 47 Magnetic Resonance Spectroscopy 45 130-nm albumin-bound paclitaxel 44 Surgical Procedures, Operative 42 Leucovorin 38 anlotinib 36 Pemetrexed 36 Biopsy 36 fludarabine 35 lenvatinib 33 Standard of Care 33 Radiosurgery 33 Irinotecan 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡